Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
The Role of Long Non-coding RNA in Solid Tumors
share announcement

The Role of Long Non-coding RNA in Solid Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 4446

Special Issue Editors

Dr. Sabrina Strano

E-Mail Website
Guest Editor
Regina Elena National Cancer Institute, Rome, Italy
Interests: noncoding RNAs; biomarkers; cancer metastasis; tumor suppressors; drug repurposing
Dr. Mario Cioce

E-Mail Website
Guest Editor
Department of Medicine, University Campus Bio-Medico of Rome, Rome, Italy
Interests: translational oncology; resistance to therapy; secretome signaling; microRNAs; cell transformation; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Long non-coding RNAs (lncRNAs) are a class of highly conserved and tissue-specific, non-protein-coding RNAs longer than 200 nucleotides functioning in the posttranscriptional regulation of gene expression. LncRNAs may target multiple RNAs, and this ensures a high degree of stage- and state-specific modulation. Thus, these RNAs exert profound effects on homeostatic adaptation processes, in both physiological and pathological conditions. LncRNAs have recently been emerging as important modulators of cancer phenotype, becoming invaluable tools for both biomarker discovery and mechanistic studies of cancer. Key modules of tumor or initiation and progression, ranging from the acquisition of pro-metastatic features to metabolic reprogramming and chemoresistance, are among the functions of this growing family of molecules. This Topic Issue is focused on all aspects of the dynamic roles lncRNAs play in cancer progression by mediating adaptive response to stress and by fueling intratumoral heterogeneity, in response to internal and external clues.

In this Special Issue, original research articles and reviews are welcome.

We look forward to receiving your contributions.

Dr. Sabrina Strano
Dr. Mario Cioce
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • noncoding RNAs
  • miRNAs
  • epigenetic events
  • cancer biology
  • metastasis
  • cancer metabolism
  • angiogenesis
  • prevention
  • biomarkers
  • NGS

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

26 pages, 1942 KiB  
Review
Exploiting Long Non-Coding RNAs and Circular RNAs as Pharmacological Targets in Triple-Negative Breast Cancer Treatment
by Alina Catalina Palcau, Renata Brandi, Nikolay Hristov Mehterov, Claudio Botti, Giovanni Blandino and Claudio Pulito
Cancers 2023, 15(16), 4181; https://doi.org/10.3390/cancers15164181 - 20 Aug 2023
Viewed by 1418
Abstract
Breast cancer is one of the most frequent causes of cancer death among women worldwide. In particular, triple-negative breast cancer (TNBC) represents the most aggressive breast cancer subtype because it is characterized by the absence of molecular targets, thus making it an orphan [...] Read more.
Breast cancer is one of the most frequent causes of cancer death among women worldwide. In particular, triple-negative breast cancer (TNBC) represents the most aggressive breast cancer subtype because it is characterized by the absence of molecular targets, thus making it an orphan type of malignancy. The discovery of new molecular druggable targets is mandatory to improve treatment success. In that context, non-coding RNAs represent an opportunity for modulation of cancer. They are RNA molecules with apparently no protein coding potential, which have been already demonstrated to play pivotal roles within cells, being involved in different processes, such as proliferation, cell cycle regulation, apoptosis, migration, and diseases, including cancer. Accordingly, they could be used as targets for future TNBC personalized therapy. Moreover, the peculiar characteristics of non-coding RNAs make them reliable biomarkers to monitor cancer treatment, thus, to monitor recurrence or chemoresistance, which are the most challenging aspects in TNBC. In the present review, we focused on the oncogenic or oncosuppressor role of long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) mostly involved in TNBC, highlighting their mode of action and depicting their potential role as a biomarker and/or as targets of new non-coding RNA-based therapeutics. Full article
(This article belongs to the Special Issue The Role of Long Non-coding RNA in Solid Tumors)
►▼ Show Figures

Figure 1

13 pages, 2554 KiB  
Review
The Biological Role and Translational Implications of the Long Non-Coding RNA GAS5 in Breast Cancer
by Ilaria Grossi, Eleonora Marchina, Giuseppina De Petro and Alessandro Salvi
Cancers 2023, 15(13), 3318; https://doi.org/10.3390/cancers15133318 - 23 Jun 2023
Cited by 3 | Viewed by 1183
Abstract
The lncRNA GAS5 plays a significant role in tumorigenicity and progression of breast cancer (BC). In this review, we first summarize the role of GAS5 in cell biology, focusing on its expression data in human normal tissues. We present data on GAS5 expression [...] Read more.
The lncRNA GAS5 plays a significant role in tumorigenicity and progression of breast cancer (BC). In this review, we first summarize the role of GAS5 in cell biology, focusing on its expression data in human normal tissues. We present data on GAS5 expression in human BC tissues, highlighting its downregulation in all major BC classes. The main findings regarding the molecular mechanisms underlying GAS5 dysregulation are discussed, including DNA hypermethylation of the CpG island located in the promoter region of the gene. We focused on the action of GAS5 as a miRNA sponge, which is able to sequester microRNAs and modulate the expression levels of their mRNA targets, particularly those involved in cell invasion, apoptosis, and drug response. In the second part, we highlight the translational implications of GAS5 in BC. We discuss the current knowledge on the role of GAS5 as candidate prognostic factor, a responsive molecular therapeutic target, and a circulating biomarker in liquid biopsies with clinical importance in BC. The findings position GAS5 as a promising druggable biomolecule and stimulate the development of strategies to restore its expression levels for novel therapeutic approaches that could benefit BC patients in the future. Full article
(This article belongs to the Special Issue The Role of Long Non-coding RNA in Solid Tumors)
►▼ Show Figures

Figure 1

12 pages, 858 KiB  
Review
Long Intergenic Non-Protein Coding RNA 173 in Human Cancers
by Wei Mao, Yi Liao and Liling Tang
Cancers 2022, 14(23), 5923; https://doi.org/10.3390/cancers14235923 - 30 Nov 2022
Cited by 6 | Viewed by 1309
Abstract
Long non-coding RNAs belong to non-coding RNAs (ncRNAs) with a length of more than 200 nucleotides and limited protein-coding ability. Growing research has clarified that dysregulated lncRNAs are correlated with the development of various complex diseases, including cancer. LINC00173 has drawn researchers’ attention [...] Read more.
Long non-coding RNAs belong to non-coding RNAs (ncRNAs) with a length of more than 200 nucleotides and limited protein-coding ability. Growing research has clarified that dysregulated lncRNAs are correlated with the development of various complex diseases, including cancer. LINC00173 has drawn researchers’ attention as one of the recently discovered lncRNAs. Aberrant expression of LINC00173 affects the initiation and progression of human cancers. In the present review, we summarize the recent considerable research on LINC00173 in 11 human cancers. Through the summary of the abnormal expression of LINC00173 and its potential molecular regulation mechanism in cancers, this article indicates that LINC00173 may serve as a potential diagnostic biomarker and a target for drug therapy, thus providing novel clues for future related research. Full article
(This article belongs to the Special Issue The Role of Long Non-coding RNA in Solid Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop